What is Ramona Sequeira’s total direct and indirect share ownership in Edwards Lifesciences (EW)?

After the reported transactions, Ramona Sequeira directly holds 6,779 shares of Edwards Lifesciences Common Stock. In addition, the filing shows an indirect holding of 14,076 shares held by a trust, giving visibility into both her direct and trust-related ownership positions in the company.

Director at Edwards Lifesciences Corp (EW) receives 3,251 RSUs grant

Filing Impact

(Neutral)

Filing Sentiment

(Neutral)

Form Type

Rhea-AI Filing Summary

Edwards Lifesciences Corp director Ramona Sequeira reported an equity award and updated holdings. She received a grant of 3,251 shares of Common Stock in the form of restricted stock units at a price of $0.00 per share, classified as a grant/award acquisition. After this grant, her directly held common stock position is 6,779 shares.

The filing also shows an indirect holding of 14,076 shares of Common Stock held by trust. According to the grant terms, these restricted stock units were awarded on May 8, 2026 under the Edwards Lifesciences Corporation 2020 Nonemployee Directors Stock Incentive Program and are scheduled to become 100% vested after the earlier of one year from the grant date or the company’s next annual meeting of stockholders.

Insider Trade Summary

2 transactions reported

Mixed 2 txns

Insider Sequeira Ramona

Role null

Type	Security	Shares	Price	Value
Grant/Award	Common Stock	3,251	$0.00	--
holding	Common Stock	--	--	--

Holdings After Transaction: Common Stock — 6,779 shares (Direct, null); Common Stock — 14,076 shares (Indirect, By Trust)

Footnotes (1)

[object Object]

Key Figures

RSU grant size: 3,251 shares Grant price per share: $0.00 per share Direct holdings after grant: 6,779 shares +2 more

5 metrics

RSU grant size 3,251 shares Restricted stock units of Common Stock granted on May 8, 2026

Grant price per share $0.00 per share Price for RSU grant to director Ramona Sequeira

Direct holdings after grant 6,779 shares Total directly held Common Stock following the RSU grant

Indirect holdings by trust 14,076 shares Common Stock held indirectly by trust as reported in holding entry

Vesting percentage 100% vested RSUs become fully vested after the earlier of one year or next annual meeting

Key Terms

restricted stock units, 2020 Nonemployee Directors Stock Incentive Program, grant, award, or other acquisition, indirect ownership

4 terms

restricted stock units financial

"These restricted stock units were granted on May 8, 2026 under the Edwards Lifesciences Corporation 2020 Nonemployee Directors Stock Incentive Program."

Restricted stock units are a type of company reward where employees are promised shares of stock, but they only fully own these shares after meeting certain conditions, like staying with the company for a set time. They matter because they can become valuable assets and are often used to motivate employees to help the company succeed.

2020 Nonemployee Directors Stock Incentive Program financial

"These restricted stock units were granted on May 8, 2026 under the Edwards Lifesciences Corporation 2020 Nonemployee Directors Stock Incentive Program."

grant, award, or other acquisition financial

"transaction_code_description: Grant, award, or other acquisition"

indirect ownership financial

"total_shares_following_transaction: 14076.0000, direct_or_indirect: I, nature_of_ownership: By Trust"

Form 4 Insider Transactions: What Each Field Means →

05/08/2026 - 09:18 PM

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Sequeira Ramona

(Last)

(First)

(Middle)

ONE EDWARDS WAY

(Street)

IRVINE

CALIFORNIA

92614

(City)

(State)

(Zip)

UNITED STATES

(Country)

2. Issuer Name and Ticker or Trading Symbol
Edwards Lifesciences Corp [ EW ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director	10% Owner
	Officer (give title below)	Other (specify below)

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
05/08/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	Code	V	Amount	(A) or (D)	Price		6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
Common Stock	05/08/2026		A		3,251⁽¹⁾	A	$0.0000	6,779	D
Common Stock								14,076	I	By Trust

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares	8. Price of Derivative Security (Instr. 5)		10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)

Explanation of Responses:

1. These restricted stock units were granted on May 8, 2026 under the Edwards Lifesciences Corporation 2020 Nonemployee Directors Stock Incentive Program. They are scheduled to become 100% vested after the earlier of one year from the grant date or the Issuer's next annual meeting of stockholders.

Remarks:

This Form 4 reflects changes in beneficial ownership only; it does not identify other securities of the Issuer beneficially owned by the Reporting Person.

	Linda J. Park, Attorney-in-Fact	05/08/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)

Source: View Original Filing on SEC EDGAR

FAQ

What insider transaction did Edwards Lifesciences (EW) report for Ramona Sequeira?

Edwards Lifesciences reported that director Ramona Sequeira received a grant of 3,251 shares of Common Stock as restricted stock units. The award was recorded as a grant or other acquisition and increased her directly held common stock position to a total of 6,779 shares.

How many Edwards Lifesciences (EW) shares were granted to Ramona Sequeira and at what price?

Ramona Sequeira was granted 3,251 shares of Edwards Lifesciences Common Stock in the form of restricted stock units at a price of $0.00 per share. This reflects a compensation-related equity award rather than an open-market purchase or sale of the company’s stock.

When do Ramona Sequeira’s Edwards Lifesciences (EW) restricted stock units vest?

The restricted stock units granted to Ramona Sequeira are scheduled to become 100% vested after the earlier of one year from the May 8, 2026 grant date or Edwards Lifesciences’ next annual meeting of stockholders. This vesting schedule ties full ownership to service over that period.

Under which program were Ramona Sequeira’s Edwards Lifesciences (EW) RSUs granted?

Her restricted stock units were granted under the Edwards Lifesciences Corporation 2020 Nonemployee Directors Stock Incentive Program. This program provides equity awards to nonemployee directors, aligning their compensation with the company’s stock performance through stock-based incentives rather than cash payments alone.